Alnylam Pharmaceuticals (ALNY) Expected to Announce Earnings on Thursday

Alnylam Pharmaceuticals (NASDAQ:ALNY) is expected to be posting its quarterly earnings results before the market opens on Thursday, February 13th. Analysts expect Alnylam Pharmaceuticals to post earnings of ($0.62) per share and revenue of $580.62 million for the quarter. Investors that are interested in participating in the company’s conference call can do so using this link.

Alnylam Pharmaceuticals Price Performance

ALNY stock opened at $268.99 on Wednesday. Alnylam Pharmaceuticals has a 1 year low of $141.98 and a 1 year high of $304.39. The firm has a market capitalization of $34.69 billion, a P/E ratio of -102.67 and a beta of 0.35. The company has a debt-to-equity ratio of 31.64, a current ratio of 2.75 and a quick ratio of 2.69. The business’s 50-day moving average is $253.54 and its two-hundred day moving average is $262.97.

Analyst Upgrades and Downgrades

ALNY has been the subject of a number of analyst reports. Canaccord Genuity Group boosted their target price on shares of Alnylam Pharmaceuticals from $366.00 to $384.00 and gave the stock a “buy” rating in a research note on Friday, November 1st. Needham & Company LLC reaffirmed a “buy” rating and set a $320.00 price objective on shares of Alnylam Pharmaceuticals in a research report on Monday, January 13th. TD Cowen raised their target price on Alnylam Pharmaceuticals from $282.00 to $371.00 and gave the stock a “buy” rating in a research report on Monday, October 21st. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $300.00 price target on shares of Alnylam Pharmaceuticals in a report on Tuesday. Finally, William Blair reissued an “outperform” rating on shares of Alnylam Pharmaceuticals in a report on Tuesday, November 19th. One investment analyst has rated the stock with a sell rating, six have issued a hold rating and nineteen have assigned a buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $298.61.

Insider Buying and Selling at Alnylam Pharmaceuticals

In other Alnylam Pharmaceuticals news, EVP Tolga Tanguler sold 1,469 shares of the business’s stock in a transaction that occurred on Tuesday, November 26th. The stock was sold at an average price of $250.98, for a total transaction of $368,689.62. Following the transaction, the executive vice president now owns 13,191 shares in the company, valued at approximately $3,310,677.18. The trade was a 10.02 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CEO Yvonne Greenstreet sold 5,219 shares of the stock in a transaction that occurred on Tuesday, November 26th. The stock was sold at an average price of $250.98, for a total value of $1,309,864.62. Following the transaction, the chief executive officer now directly owns 78,880 shares of the company’s stock, valued at approximately $19,797,302.40. This trade represents a 6.21 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 73,964 shares of company stock valued at $20,622,925. 1.50% of the stock is owned by company insiders.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.